{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:46:32Z","timestamp":1777506392309,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.leukres.2016.04.003","type":"journal-article","created":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T18:31:23Z","timestamp":1460399483000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Azacitidine versus decitabine in patients with refractory anemia with excess blast\u2014Results of multicenter study"],"prefix":"10.1016","volume":"45","author":[{"given":"Ozan","family":"Salim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayfur","family":"Toptas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esin","family":"Avsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan Kemal","family":"Yucel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erman","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burhan","family":"Ferhanoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayfer","family":"Geduk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozgur","family":"Mehtap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Tombak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyup Naci","family":"Tiftik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burak","family":"Deveci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdal","family":"Kurtoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Kara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isik Kaygusuz","family":"Atagunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulin Firatli","family":"Tuglular","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"Undar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.04.003_bib0005","series-title":"WHO Classification of Tumors of Hematopoetic and Lymphoid Tissues","first-page":"100","author":"Swerdlow","year":"2008"},{"issue":"September (9)","key":"10.1016\/j.leukres.2016.04.003_bib0010","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ajh.24102","article-title":"Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Garcia-Manero","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"March (11)","key":"10.1016\/j.leukres.2016.04.003_bib0015","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.04.003_bib0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"February (2)","key":"10.1016\/j.leukres.2016.04.003_bib0025","doi-asserted-by":"crossref","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PLoS One"},{"issue":"May (8)","key":"10.1016\/j.leukres.2016.04.003_bib0030","first-page":"1111","article-title":"Keating azacitidine a review of its use in higher-risk myelodysplastic syndromes\/acute myeloid leukaemia","volume":"72","author":"Gillian","year":"2012","journal-title":"Drugs"},{"issue":"June (6)","key":"10.1016\/j.leukres.2016.04.003_bib0035","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/leu.2008.397","article-title":"The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells","volume":"23","author":"Flotho","year":"2009","journal-title":"Leukemia"},{"issue":"September (9)","key":"10.1016\/j.leukres.2016.04.003_bib0040","article-title":"Equitoxic doses of 5-azacytidine and 5-aza-2\u2032-deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome","volume":"5","author":"Qiu","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.leukres.2016.04.003_bib0045","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/0145-2126(84)90059-6","article-title":"Comparison of the antileukemic acitivity of 5-aza- 2\u2032-deoxycytidine, 1-\u03b2-d-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia","volume":"8","author":"Momparler","year":"1984","journal-title":"Leuk. Res."},{"issue":"January (1)","key":"10.1016\/j.leukres.2016.04.003_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2400526","article-title":"Continuous infusion of low-dose 5-Aza-2\u2032-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome","volume":"11","author":"Wijermans","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.04.003_bib0055","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the Alternative Dosing for Outpatient Treatment (ADOPT) trial","volume":"27","author":"Steensma","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.04.003_bib0060","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ajh.21482","article-title":"A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes","volume":"84","author":"Martin","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2016.04.003_bib0065","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/j.1349-7006.2011.01993.x","article-title":"Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes","volume":"102","author":"Uchida","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.leukres.2016.04.003_bib0070","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/j.1349-7006.2012.02386.x","article-title":"Phase I\/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan","volume":"103","author":"Oki","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.leukres.2016.04.003_bib0075","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1200\/JCO.2012.44.6823","article-title":"Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes","volume":"31","author":"Garcia-Manero","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.04.003_bib0080","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.04.003_bib0085","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.04.003_bib0090","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2016.04.003_bib0095","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"Lubbert","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2016.04.003_bib0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3324\/haematol.2009.010611","article-title":"5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome\u2014systematic review and meta-analysis","volume":"95","author":"Gurion","year":"2010","journal-title":"Haematologica"},{"issue":"February (2)","key":"10.1016\/j.leukres.2016.04.003_bib0105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3324\/haematol.2009.017764","article-title":"Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis","volume":"95","author":"Kumar","year":"2010","journal-title":"Haematologica"},{"issue":"Jan 1","key":"10.1016\/j.leukres.2016.04.003_bib0110","first-page":"22","article-title":"Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants","volume":"15","author":"Mixue Xie Jiang","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2016.04.003_bib0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.12256","article-title":"Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes","volume":"161","author":"Lee","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.04.003_bib0120","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00277-013-1702-8","article-title":"Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome","volume":"92","author":"Lee","year":"2013","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2016.04.003_bib0125","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2016.04.003_bib0130","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2016.04.003_bib0135","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.04.003_bib0140","series-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"2","key":"10.1016\/j.leukres.2016.04.003_bib0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2016.04.003_bib0150","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2016.04.003_bib0155","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.04.003_bib0160","series-title":"PSMATCH2: Stata Module to Perform Full Mahalanobis and Propensity Score Matching, Common Support Graphing, and Covariate Imbalance Testing","author":"Leuven","year":"2010"},{"issue":"5","key":"10.1016\/j.leukres.2016.04.003_bib0165","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"issue":"September (9)","key":"10.1016\/j.leukres.2016.04.003_bib0170","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.leukres.2015.06.007","article-title":"Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia","volume":"39","author":"Fozza","year":"2015","journal-title":"Leuk. Res."},{"issue":"February (2)","key":"10.1016\/j.leukres.2016.04.003_bib0175","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.leukres.2014.08.016","article-title":"The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome","volume":"39","author":"WU","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2016.04.003_bib0180","series-title":"57th ASH Annual Meeting and Exposition","article-title":"Differential response to hypomethylating agents based on sex: a report on behalf of the MDS clinical research consortium (MDS CRC)","author":"DeZern","year":"2015"},{"issue":"May (5)","key":"10.1016\/j.leukres.2016.04.003_bib0185","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.leukres.2015.03.006","article-title":"Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up","volume":"39","author":"Cabrero","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2016.04.003_bib0190","series-title":"57th ASH Annual Meeting and Exposition","article-title":"Comparative effectiveness of azacitidine versus decitabine among older adults diagnosed with higher-risk myelodysplastic syndromes (HR-MDS)","author":"Zeidan","year":"2015"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616300431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T13:10:44Z","timestamp":1600434644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616300431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":38,"alternative-id":["S0145212616300431"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.04.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azacitidine versus decitabine in patients with refractory anemia with excess blast\u2014Results of multicenter study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}